DexCom (DXCM) News Today

DexCom (NASDAQ:DXCM - Get Free Report) announced its quarterly earnings data on Thursday. The medical device company reported $0.43 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.04. The firm had revenue of $1 billion during the quarter, compared to analysts' expectations of $1.04 billion. DexCom had a return on equity of 31.01% and a net margin of 16.82%. The company's quarterly revenue was up 15.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.34 EPS.

BTIG Research decreased their price objective on shares of DexCom from $156.00 to $120.00 and set a "buy" rating on the stock in a report on Friday.

DexCom (NASDAQ:DXCM) Hits New 52-Week Low on Analyst Downgrade

Healthcare of Ontario Pension Plan Trust Fund cut its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 73.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 5,767 shares of the medical device company's stock aft

JPMorgan Chase & Co. lowered shares of DexCom from an "overweight" rating to a "neutral" rating and decreased their price target for the stock from $145.00 to $75.00 in a research report on Friday.

CANADA LIFE ASSURANCE Co grew its position in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 3.3% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 298,413 shares of the medical device company's stoc

Bessemer Group Inc. cut its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 28.0% in the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 955,161 shares of the medical device company's stock after selling 372,228 shares d

Canaccord Genuity Group reaffirmed a "buy" rating and set a $145.00 target price on shares of DexCom in a research report on Tuesday.

Vanguard Group Inc. increased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 0.3% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 44,603,745 shares of the medical device company's stock after pu

M&G Plc purchased a new stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 58,485 shares of the medical device company's stock, valued at approxima

Beacon Investment Advisory Services Inc. decreased its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 1.8% during the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 744,066 shares of the medical device company'

DexCom (NASDAQ:DXCM) will be releasing earnings after the market closes on Thursday, July 25, Zacks reports. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=494589)

ProShare Advisors LLC grew its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 20.6% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 434,052 shares of the medical device company's stock after

Shares of DexCom, Inc. (NASDAQ:DXCM - Get Free Report) have earned an average recommendation of "Moderate Buy" from the fifteen ratings firms that are presently covering the firm, Marketbeat.com reports. Three analysts have rated the stock with a hold recommendation, eleven have assigned a buy rec

Swiss National Bank lessened its holdings in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 4.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,157,100 shares of the medical device company's stock after selling 55,800 sha

TimesSquare Capital Management LLC cut its stake in DexCom, Inc. (NASDAQ:DXCM - Free Report) by 7.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 714,680 shares of the medical device company's stoc

Stifel Nicolaus decreased their price target on shares of DexCom from $145.00 to $132.00 and set a "buy" rating for the company in a report on Friday.

The healthcare industry represents a substantial and dynamic market sector, presenting many opportunities for investors seeking long-term growth and stability. Factors such as the aging population, technological advances, and rising healthcare costs provide the sector with a compelling combination of growth potential and resilience.